The long-sought discovery of HER2 as an actionable and highly sensitive therapeutic target was a major breakthrough for the treatment of highly aggressive HER2-positive breast cancer, leading to approval of the first HER2-targeted drug — the monoclonal antibody trastuzumab — almost 25 years ago....
Even though randomized controlled clinical trials demonstrated improved survival by adjuvant trastuzumab treatment of HER2-positive breast cancer patients, data on its effect in clinical routine are scarce. This study evaluated the use and efficacy of t...
Herceptin is approved for the treatment of adults with early-stage breast cancer that isHumanEpidermal growth factorReceptor2-positive (HER2+) and has spread into the lymph nodes, or is HER2-positive and has not spread into the lymph nodes. If it has not spread into the lymph nodes, the ...
Download helpful NERLYNX resources. Hear real patient stories and learn about programs to support HER2+ breast cancer patients. See safety/patient info on site.
[4]Schettini,F.et al.Clinical,pathological,and PAM50 gene expression features of HER2-low breast cancer.NPJ Breast Cancer 7,1. [5]Horisawa,N.et al.The frequency of low HER2 expression in breast cancer and a comparison of prognosis between patients with HER2-low and HER2-negative breast can...
6、RUGO HS,LEREBOURS F,CIRUELOS E,et al.Alpelisib plus fulvestrant in PlK3CA-mutated,hormone recep-tor-positive advanced breast cancer after a CDK4/6 inhibitor(BYLieve):One cohort of a phase 2,multicentre,open-label,non-comparative study.Lancet Oncol,2021,22(4):489-498. 7、TURNER NC,OLI...
组织HER2阴性原发肿瘤患者可能获得HER2阳性的CTC,其比CTC HER2阴性表现出更强的增殖潜力。此外,HER2阳性和HER2阴性的CTC在治疗过程中可能自发相互转化,这提示了潜在的耐药机制。发表在《Breast Cancer Research and Treatment》杂志上名为《Prognostic value of HER2 status on circulating tumor cells in advanced-stage...
HER2+breast cancertargeted therapytrastuzumabacquired resistancecell lineresistance modelBackground: Overexpression and amplification of thdoi:info:doi/10.2174/0929867323666161216144659Gonzalez-Alonso, PaulaCristobal, IonZazo, SandraMartin-Aparicio, Ester
Human epidermal growth factor receptor 2 (HER2) is overexpressed in approximately 20% of all breast cancers. Before the development of HER2-directed monoclonal antibodies, HER2-positive breast cancer was associated with a rather poor prognosis. With the advent of monoclonal HER2-targeting antibodies (...
Expression and clinical significance of KIF20A in HER2-positive breast cancer WangYanli ZhangAimin ChangYanmin Authors Info & Affiliations Published:2021-06-28· DOI:10.3760/cma.j.cn121382-20210110-00304 0 0 0 0 0 0 PDF下载 摘要 目的探讨驱动蛋白家族成员20A(KIF20A)在人表皮生长因子受体2(HER2)过...